Clinical Trial Update: Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients

View source ↗

Summary

Observational update describing adherence to daily Ventavis (iloprost) use via the Insight program in Class III pulmonary arterial hypertension patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ventavis (iloprost)

Snippet

Sponsor: Bayer | Conditions: Pulmonary Arterial Hypertension | Status: COMPLETED